Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh
Rotavirus Vaccine
103992
NCT00139334
Infections, Rotavirus
Phase 2
 
An annotated case report form is not available for this study. A blank case report form will be provided.
January 2014

Powered by ideaPoint, Inc.